Tag Archives: Jason Mccarthy

Maxim Group Issues a Buy Rating on Cardiff Oncology (CRDF)

Maxim Group analyst Jason McCarthy assigned a Buy rating to Cardiff Oncology (CRDF – Research Report) yesterday and set a price target of $30.00. The company’s shares closed last Friday at $9.49. According to TipRanks.com, McCarthy is a 5-star analyst

GeoVax Labs (GOVX) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to GeoVax Labs (GOVX – Research Report) yesterday and set a price target of $8.00. The company’s shares closed last Friday at $5.95. According to TipRanks.com, McCarthy is a 5-star analyst

9 Meters Biopharma (NMTR) Receives a New Rating from Maxim Group

Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on 9 Meters Biopharma (NMTR – Research Report) yesterday and set a price target of $3.00. The company’s shares closed last Wednesday at $1.31. According to TipRanks.com, McCarthy is

Maxim Group Sticks to Their Buy Rating for Achieve Life Sciences (ACHV)

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Achieve Life Sciences (ACHV – Research Report) yesterday and set a price target of $21.00. The company’s shares closed last Friday at $11.65. According to TipRanks.com, McCarthy is a top

Maxim Group Reiterates a Buy Rating on Lineage Cell Therapeutics (LCTX)

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Lineage Cell Therapeutics (LCTX – Research Report) yesterday and set a price target of $5.00. The company’s shares closed last Friday at $2.48. According to TipRanks.com, McCarthy is a top

Analysts Are Bullish on These Healthcare Stocks: Karuna Therapeutics (KRTX), Sensus Healthcare (SRTS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karuna Therapeutics (KRTX – Research Report) and Sensus Healthcare (SRTS – Research Report) with bullish sentiments. Karuna Therapeutics (KRTX) In a report